Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
lactobacillus salivarius PS11603 + bifidobacterium longum PS10402
- Development stage
- Unknown
- Lead developer
- Morinaga Milk Industry
- Modality
- Synthetic Biology Platforms → Engineered Microbial Therapeutics → Microbiome Therapeutics, Fresh FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Yeast Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Bacterial Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Defined Consortia → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Frozen FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Genetically Modified Bacteria → Engineered Microbial Therapeutics → Microbiome Therapeutics, Microbial Metabolites → Microbiome-Derived Products → Microbiome Therapeutics, Microbial Proteins → Microbiome-Derived Products → Microbiome Therapeutics, Complex Communities → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics
- Administration
- Oral
01
Overview
A probiotic combination therapy comprising the specific bacterial strains *Ligilactobacillus salivarius* PS11603 (formerly *Lactobacillus salivarius*) and *Bifidobacterium longum* subsp. *infantis* PS10402. Developed by Bened Biomedical, this formulation is designed to promote the early establishment of a healthy intestinal microbiota in preterm infants, who often experience delayed or abnormal gut colonization. The product is a biologic probiotic formulation containing live bacterial strains. In a randomized, double-blind, placebo-controlled clinical trial (NCT03701906), the combination demonstrated the ability to enhance earlier colonization of *Lactobacillus* and *Bifidobacterium* species in the guts of preterm infants compared to placebo. By establishing these beneficial microbes, the therapy aims to support immune development and gut barrier function in this vulnerable population.
- Other names
- Ligilactobacillus salivarius PS11603 + Bifidobacterium longum subsp. infantis PS10402L. salivarius PS11603 + B. longum PS10402Lactobacillus salivarius PS11603 + Bifidobacterium longum PS10402
Beyond the preview
Go deeper on lactobacillus salivarius PS11603 + bifidobacterium longum PS10402.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on lactobacillus salivarius PS11603 + bifidobacterium longum PS10402.